0
Article |

Griseofulvin in the Treatment of Some Deep Mycoses

F. LATAPÍ, M.D.
Arch Dermatol. 1960;81(5):841-848. doi:10.1001/archderm.1960.03730050197036.
Text Size: A A A
Published online

Soon after the first reports on griseofulvin therapy of skin mycoses we began to use this new drug in Mexico. Our results on dermatophytoses23 are similar to those of other investigators and they are not the subject of this paper.

The action of griseofulvin on deep mycoses was not or scarcely considered in the early studies, because in in vitro observations, Sporotrichum schenckii and other fungi were found insensitive.3 As deep mycoses are frequent in Mexico we decided, however, to study their response to this therapy. This paper is a preliminary report on this matter.

Griseofulvin, as it is well known, was first isolated by Oxford, Raistrick, and Simonart25 in 1939 as a metabolic product from Penicillium griseofulvum. In 1946, Brian et al.6 described a fungistatic "curlingfactor" obtained from Penicillium janczewskii, and its identity with griseofulvin was established by Grove and McGowan13 the following year.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 21

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs